Paola Manara

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors

Charles H. Li, Elena Bonazzoli, Stefania Bellone et al. · Proceedings of the National Academy of Sciences · 2018 · 99 citations · Full text

Medicine, Cancer Biology, Oncology +17

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

Luca Zammataro, Salvatore Lopez, Stefania Bellone et al. · Proceedings of the National Academy of Sciences · 2019 · 94 citations · Full text

Medicine, Genetics, Oncology +17

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

Emanuele Perrone, Salvatore Lopez, Burak Zeybek et al. · Frontiers in Oncology · 2020 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

Burak Zeybek, Aránzazu Manzano, Anna Bianchi et al. · Scientific Reports · 2020 · 62 citations · Full text

Medicine, Oncology, Pharmacology +16

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas

Salvatore Lopez, Emanuele Perrone, Stefania Bellone et al. · Oncotarget · 2020 · 50 citations · Full text

Medicine, Oncology, Pharmacology +17